Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (8833)	2/24/1999 7:15:00 AM
From: Robert K.	Read Replies (2) \| Respond to of 17367

Dr C.>What you forgot there was the seeming ability of rBPI21 to go unnoticed by anca to bpi. A HUGE point. A tougher bpi. Ahhh. but are the inflamation in those conditions due from the lps in the bacteria? Or the lack of the bodies ability for the natural bpi to clean up and regulate those bacteria? Agree with you 100% Plus on the point that if bpi21 is approved, process will accelerate. Geez, the way they are testing it now, imagaine if it becomes available to the docs to use. Question more is how will they limit and slow down testing IMO. All disclaimers. Always.